O-10 Trastuzumab with trimodality treatment for esophageal adenocarcinoma with HER2 overexpression: NRG Oncology/RTOG 1010. - Ilson, D.; Moughan, J.; Safran, H.; Wigle, D.; Depetrillo, T.; Haddock, M.; Hong, T.; Leichman, L.; Rajdev, L.; Resnick, M.; Kachnic, L.; Seaward, S.; et al. (Annals of Oncology, 2020)